OncoMatch/Clinical Trials/NCT07121374
NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study
Is NCT07121374 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Neoadjuvant chemo-immunotherapy for pleural epithelioid mesothelioma.
Treatment: Neoadjuvant chemo-immunotherapy — The goal of this clinical trial is to evaluate whether a combination of chemotherapy and immunotherapy can make surgery possible in adults with inoperable pleural mesothelioma (a type of cancer affecting the lung lining). The main questions it aims to answer are: Can two cycles of neoadjuvant chemotherapy and dual immunotherapy, followed by surgery, be completed safely and effectively? Does this treatment allow previously inoperable patients to become eligible for surgery and improve survival outcomes? Participants will: Receive two cycles of chemotherapy (cisplatin or carboplatin and pemetrexed) Receive dual immunotherapy (nivolumab and ipilimumab) Undergo evaluation by a multidisciplinary team to determine if surgery is possible If operable, undergo extended pleurectomy/decortication surgery Be followed for one year to assess side effects, quality of life, and survival
Check if I qualifyExtracted eligibility criteria
Cancer type
Mesothelioma
Disease stage
Excluded: Stage SOME T3, ALL T4
cT2-3 N0-1 M0 according to UICC TNM 9 and considered inoperable by the Multidisciplinary Tumor Board ... Exclusion: TNM 9 criteria (T1) or inoperable PM patients who will not have a chance to become operable after neoadjuvant treatment according to TNM 9 criteria (some T3, all T4, N2-3, M1)
Performance status
WHO 0–1
Prior therapy
Cannot have received: chemotherapy
Cannot have received: immunotherapy
Cannot have received: surgery
Exception: diagnostic thoracoscopy
Cannot have received: radiation therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify